Loading clinical trials...
Loading clinical trials...
A Phase 1b/2a, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MB-001 in Participants With Moderately to Severely Active Ulcerative Colitis
Conditions
Interventions
MB-001
Matching placebo to MB-001
Locations
1
Moldova
Site 3001
Chisinau, Moldova
Start Date
April 1, 2026
Primary Completion Date
July 1, 2028
Completion Date
August 1, 2028
Last Updated
April 14, 2026
NCT07271069
NCT07245394
NCT07333716
NCT06896305
NCT07350577
NCT07269223
Lead Sponsor
Mage Biologics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions